1. Introduction {#s0005}
===============

Metabolic engineering can serve to convert microorganisms into microbial cell factories to biotechnologically produce desired compounds like chemicals, pharmaceuticals and food ingredients. The yeast *Saccharomyces cerevisiae* can be easily modified by a large amount of available molecular biology tools. Although higher titers and yields are often reached with bacterial hosts ([@bib2]), the robustness of *S. cerevisiae* and its stress tolerance in fermentative processes ([@bib20]) represent distinct advantages of this yeast ([@bib53]).

We recently published a metabolic engineering approach allowing for the production of the aromatic fine chemicals mandelic acid (MA) and hydroxymandelic acid (HMA) in *S. cerevisiae* ([@bib43]). Prior to that, three studies focused on the production of MA or MA derivatives in *Escherichia coli* ([@bib32], [@bib35], [@bib49]). MA finds use in the cosmetic industry and serves as a precursor for the production of pharmaceutically active compounds ([@bib8], [@bib17], [@bib34], [@bib37], [@bib46], [@bib52]). MA production in *E. coli* and *S. cerevisiae* was achieved by introducing heterologous hydroxymandelate synthases (HmaS), which convert phenylpyruvate, the precursor of phenylalanine, to MA ([@bib32], [@bib35], [@bib43], [@bib49]). However, hydroxymandelate synthases have a much higher affinity towards their native substrate hydroxyphenylpyruvate, the precursor of tyrosine, which they convert to hydroxymandelic acid (HMA) ([@bib43], [@bib49]). Consequently, in fermentations with strains exhibiting an intact tyrosine biosynthetic pathway mainly HMA will be formed. Therefore, all MA production strains published so far, carried disruptions in the tyrosine biosynthetic pathway ([@bib32], [@bib35], [@bib43], [@bib49]). As feeding of tyrosine to the medium would increase production costs, our goal was to construct an *S. cerevisiae* MA producer strain that does not require supplementation of tyrosine. After our attempts to rationally engineer the active site of HmaS to increase affinity for phenylpyruvate and decrease the conversion of hydroxyphenylpyruvate did not yield satisfactory results ([@bib43], and this study), we shifted our focus to metabolic engineering strategies to improve MA production. We aimed to increase flux into the phenylalanine pathway and decrease flux into the tyrosine pathway without inhibiting tyrosine synthesis completely.

The core of the aromatic amino acid biosynthesis pathway in *S. cerevisiae* is the shikimic acid pathway ([@bib4]). Chorismate, which originates from the shikimic acid pathway, represents the last common precursor of the three aromatic amino acids tryptophan, phenylalanine and tyrosine (see [Fig. 1](#f0005){ref-type="fig"}). Chorismate is either converted by Trp2/Trp3 to anthranilate, thereby entering the tryptophan biosynthetic pathway, or by the chorismate mutase Aro7 to prephenate. Prephenate, the last common intermediate of the biosynthetic pathways of phenylalanine and tyrosine, is either converted by the prephenate dehydratase Pha2 to phenylpyruvate or by the prephenate dehydrogenase Tyr1 to hydroxyphenylpyruvate ([Fig. 1](#f0005){ref-type="fig"}). Phenylpyruvate and hydroxyphenylpyruvate are both substrates of the transaminases Aro8 and Aro9, which convert them to phenylalanine and tyrosine, respectively ([@bib4]). The degradation of phenylalanine and tyrosine is carried out via the Ehrlich pathway and results in the production of fusel alcohols and the corresponding acids ([Fig. 1](#f0005){ref-type="fig"})([@bib25]).Fig. 1Applied modifications of the aromatic amino acid pathway of *S. cerevisiae* for mandelic acid production. The heterologous hydroxymandelate synthase (HmaS, red) converts the intermediates of the aromatic amino acid pathway phenylpyruvate (PPY) and hydroxyphenylpyruvate (HPP) to mandelic acid (MA) and hydroxymandelic acid (HMA), respectively. Enzymes that were targeted to mitochondria/peroxisomes in our compartmentalization approach are marked with a star. The compartment (mitochondrion or peroxisome) containing the three consecutive enzymes Aro7^fbr^, Pha2 and HmaS is depicted as a grey area surrounded by a dashed line. The bifunctional *E. coli* enzyme PheA^fbr^ is indicated in orange (CM, chorismate mutase; PDT, prephenate dehydratase). Dashed arrows indicate multiple enzymatic steps. Enzymes whose genes were deleted in a part of the strains used in this work are labeled in grey. ANTH, anthranilate; Trp, tryptophan; PAC, phenylacetaldehyde; pPAC, *p*-hydroxyphenylacetaldehyde; Phe, phenylalanine; Tyr, tyrosine; PAA, phenylacetic acid; pPAA, *p*-hydroxyphenylacetic acid; PET, phenylethanol; pPET, *p*-hydroxyphenylethanol.Fig. 1

Aiming to construct a tyrosine prototrophic *S. cerevisiae* MA producer strain we tested two metabolic engineering approaches -- using pathway compartmentalization and using the heterologous, bifunctional *E. coli* enzyme PheA.

Compartmentalization of metabolic pathways in yeast organelles has been successfully used to increase yields of various industrially relevant products (reviewed by [@bib24]). Compartmentalizing pathways can be advantageous due to the special environment inside of an organelle (e.g. substrate or cofactor availability, pH, etc.), because of shorter diffusion distances, high protein content or the spatial separation from enzymes present in the cytosol. In our approach, we mainly aimed to spatially separate the MA production pathway (Aro7, Pha2, HmaS) from competing enzymes like Tyr1, from the Ehrlich pathway enzymes and from the competing substrate hydroxyphenylpyruvate (compare [Fig. 1](#f0005){ref-type="fig"}). We chose to test compartmentalization of the pathway in mitochondria and peroxisomes -- two organelles which substantially differ in their physicochemical environment ([@bib11], [@bib26], [@bib38], [@bib51]) and their permeability ([@bib9], [@bib12]) but have both been successfully used for pathway compartmentalization approaches in *S. cerevisiae* ([@bib24]).

In our second metabolic engineering approach for the production of MA in a tyrosine prototrophic *S. cerevisiae* strain we used the bifunctional *E. coli* enzyme PheA in a feedback resistant version (PheA^fbr^). In contrast to the aromatic amino acid pathway of *S. cerevisiae*, in *E. coli* phenylpyruvate and hydroxyphenylpyruvate are formed by bifunctional enzymes, PheA and TyrA, respectively ([@bib27], [@bib44]). Both enzymes exhibit chorismate mutase activity, and PheA additionally exhibits prephenate dehydratase activity whereas TyrA additionally exhibits prephenate dehydrogenase activity. By using PheA^fbr^ in an *aro7Δ S. cerevisiae* strain we aimed to increase flux into the phenylalanine biosynthetic pathway and decrease levels of hydroxyphenylpyruvate. We assumed that there might be a channeling effect caused by a transfer of the intermediate prephenate formed by the chorismate mutase domain to the prephenate dehydratase domain of PheA^fbr^, thereby favoring entry into the phenylalanine branch (compare [Fig. 1](#f0005){ref-type="fig"}).

Whereas the introduced mutations in the active site of HmaS did not yield the desired positive effect on MA production, we demonstrate that the two metabolic engineering strategies -- compartmentalization and *pheA*^*fbr*^ expression -- successfully resulted in a shift from HMA to MA production without causing tyrosine auxotrophy. Of these two strategies, using the bifunctional PheA enzyme led to much higher MA titers compared to the mitochondrial and peroxisomal compartmentalization strategy.

2. Material and methods {#s0010}
=======================

2.1. Plasmid and strain construction {#s0015}
------------------------------------

Plasmids and *S. cerevisiae* strains used in this study are listed in [Supplementary tables S1 and S2](#s0075){ref-type="sec"}, respectively. For subcloning electrocompetent *E. coli* DH10β (Gibco BRL, Gaithersburg, MD) were used according to [@bib14]. *E. coli* transformants were selected on lysogeny broth (LB) agar plates ([@bib45]) containing 100 mg/L ampicillin. Plasmids were constructed with Gibson assembly ([@bib21]) or homologous recombination. The respective empty vectors were linearized with *SacI* and *BamHI* and then used for Gibson assembly or transformation together with the according PCR-fragments. *S. cerevisiae* was transformed according to the protocol of [@bib22]. All primers used in this study are listed in [Supplementary table S3](#s0075){ref-type="sec"}.

To receive a feedback-resistant variant of PheA (Uniprot accession number P0A9J8) the mutations ΔT304, G305K and ΔQ306 ([@bib36]) were introduced. The gene was codon-optimized according to [@bib56] and ordered as a String DNA fragment from Thermo Fischer Scientific Germany with 30 base pairs overhangs to both the *HXT7* promoter and the *CYC1* terminator. The enhanced peroxisomal targeting sequence (ePTS1, [@bib12]) was codon-optimized ([@bib56]) and introduced by the primers MRP232--234. The mitochondrial targeting sequence (MTS, amino acids 1--69 of *Neurospora crassa* F~0~ ATP synthase subunit 9, GenBank accession number CAA24230) was codon-optimized with the DNA 2.0 software and ordered from the company DNA 2.0. The DNA sequences of codon-optimized *pheA*^*fbr*^, MTS and ePTS1 can be found in [Supplementary table S4](#s0075){ref-type="sec"}. To receive a feedback resistant form of Aro7 (Aro7^fbr^, [@bib47]) the mutation G141S was introduced by the primers MGP11 and MGP12. All constructs were confirmed by sequencing (GATC Biotech, Germany).

Strains constructed in this study and their parent strains are listed in [Supplementary table S2](#s0075){ref-type="sec"}. Shik↑ indicates the genotype *aro4Δ*::*HXT7*~*pr*~*-ARO1 ura3Δ::TPI1*~*pr*~*-ARO4*^*fbr*^*\_HXT7*~*pr*~*-ARO3*^*fbr*^ resulting in an overexpression of *ARO1* and of the feedback resistant versions of *ARO4* and *ARO3 a*s published in [@bib43]. Genomic deletions were performed with the CRISPR/Cas9 system as described in [@bib18]. Cells were selected on YPD medium containing antibiotics G418 (200 mg/L) or clonNAT/Nourseothricin (100 mg/L). The gRNA sequences chosen for the deletions are listed in [Supplementary table S5](#s0075){ref-type="sec"}. The genomic reintegration of *TRP2* into strain MRY31 (CEN.PK2-1C *TRP1* Shik↑ *aro10Δ aro8Δ pdc5Δ trp2Δ aro7*Δ) to yield the tryptophan prototrophic strain MRY36 was achieved by simply transforming the *TRP2*-PCR product with overhang to *TRP2* promoter and terminator and selecting the cells on plates lacking tryptophan.

All experiments were done using the codon-optimized *hmaS* from *Nocardia uniformis* as this enzyme performed best in *S. cerevisiae* in our recent study ([@bib43]).

2.2. Strain cultivation {#s0020}
-----------------------

*S. cerevisiae* strains were always freshly transformed and plated onto synthetic complete medium (SCD, 20 g/L glucose, as described in [@bib6] omitting leucine, histidine and/or uracil according to auxotrophic requirements.

For fermentations, precultures (75 ml in 300 ml flasks) and main cultures (20 ml in 100 ml flasks) were grown in synthetic minimal medium (SMD, 1.7 g/L Difco yeast nitrogen base without amino acids and 5 g/L ammonium sulfate, 20 g/L glucose, 20 mM KH~2~PO~4~, pH 6.3), and uracil (0.171 mM) and histidine (0.124 mM) were added when required. The precultures of the compartmentalization fermentation (results in [Fig. 3](#f0015){ref-type="fig"}C and D) were supplemented with additional aromatic amino acids (0.160 mM tyrosine, 0.582 mM phenylalanine, 0.2 mM anthranilate as precursor for tryptophan) to ensure comparable growth of all strains. Precultures were harvested in the exponential phase, washed and resuspended to an optical density (λ = 600 nm) of 5. The optical density at 600 nm (OD~600~) was analyzed with a spectrophotometer (Ultrospec 2100 pro spectrophotometer, GE Healthcare, USA). All fermentations were performed in biological duplicates.

For the growth tests on agar plates cells were resuspended in H~2~O, washed once, brought to an OD~600~ of 1, and dilution series were generated (OD~600~ of 0.1, 0.01 and 0.001). 4 µl of the cell suspensions were then dropped onto SCD or SMD agar plates containing different combinations of the aromatic amino acids tyrosine, phenylalanine and tryptophan. Pictures of the plates were taken after 3 days of incubation at 30 °C.

2.3. Metabolite analysis {#s0025}
------------------------

Samples of the supernatant for metabolite analysis were obtained by centrifugation and stored at −20 °C until analyzed. Samples for glucose and ethanol analysis were treated and analyzed as described previously ([@bib43]).

For the analysis of MA and HMA, acetonitrile was added to the samples to a final concentration of 20%. Quantification was performed using an HPLC (Dionex) equipped with an Agilent Zorbax SB-C8 column (4.6 × 150 mm, 3.5 µm) at 40 °C. The samples were analyzed under the following gradient of eluent A (0.1% (v/v) formic acid) and eluent B (acetonitrile with 0.1% (v/v) formic acid): 2 min 0% B, 13 min linear gradient to 10% B, 5 min linear gradient to 25% B, 4 min 25% B, 1 min linear gradient to 0% B, 5 min 0% B. The flow rate was 1 ml/min. MA was detected at 190 nm (compartmentalization approach, [Fig. 3](#f0015){ref-type="fig"}C and D) or 200 nm (PheA approach, [Fig. 4](#f0020){ref-type="fig"}B, C and D), HMA was detected at 200 nm and phenylacetic acid and phenylethanol eluted together and were detected at 215 nm (Dionex UlitMate 3000 Variable Wavelength Detector). The standard solutions for phenylacetic acid and phenylethanol calibration contained the same amount of phenylacetic acid and phenylethanol (w/v) as described previously ([@bib43]). MA, phenylethanol and phenylacetic acid were purchased from Sigma Aldrich (778052, 77861 and P16621, respectively) and HMA was purchased from Tokyo Chemical Industry Co. (H0060). Data analysis and graphing were performed with the software Prism 5 (GraphPad, USA).

2.4. Fluorescence microscopy {#s0030}
----------------------------

For fluorescence microscopy CEN.PK2-1C harboring the *MTS-ARO7*^*fbr*^*-sfGFP* or the *sfGFP-ARO7*^*fbr*^*-ePTS1* plasmid were grown in low fluorescence SCD medium (lf-SCD) containing 6.9 g/L yeast nitrogen base (YNB) with ammonium sulfate, without amino acids, without folic acid and without riboflavin (MP Biomedicals), 20 g/L glucose and amino acids as stated in [@bib6], omitting uracil. The medium was filter-sterilized. Cells were grown to the exponential phase, then diluted 1:1 with fresh lf-SCD containing 0.6% low melting agarose (Roth) and applied to the glass microscope slide. Samples were analyzed with the confocal laser scanning microscope ZEISS LSM 780 with objective plan-apochromat 63 × /1.40 Oil DIC M27 and excitation at 488 nm and an emission bandwidth of 493--598 nm.

3. Results and discussion {#s0035}
=========================

3.1. Engineering hydroxymandelate synthase HmaS for mandelic acid production {#s0040}
----------------------------------------------------------------------------

HmaS converts hydroxyphenylpyruvate to HMA and, less preferred, phenylpyruvate to MA ([@bib43], [@bib49]). Apart from completely blocking the tyrosine biosynthetic pathway, one approach to specifically produce MA would be to prevent hydroxyphenylpyruvate from binding to HmaS and to simultaneously increase the conversion of phenylpyruvate. A serine in the active site of HmaS forms a hydrogen bond to the *para*-hydroxy group of its favored substrate hydroxyphenylpyruvate ([@bib5]). In our previous work on MA and HMA production in *S. cerevisiae*, we mutated this serine to hydrophobic amino acids to decrease affinity for hydroxyphenylpyruvate and optimize the HmaS active site for phenylpyruvate binding with the goal of improving specific MA production. The most promising exchange (S201V, *A. orientalis* HmaS) increased MA production but only to relatively low MA titers (4 mg/L). This suggested that the low turnover of phenylpyruvate by the HmaS^S201V^ variant cannot be attributed solely to the competition with hydroxyphenylpyruvate for the active site, but rather to mechanistic constraints or a severe alteration of the active site by the substitution of serine to valine. In the present work, we therefore tested a more moderate substitution (serine to cysteine). We chose the *N. uniformis* HmaS as this enzyme had been shown to promote higher production of MA/HMA in yeast ([@bib43]). With the serine to cysteine mutation (HmaS^S195C^) we solely replaced an OH hydroxy group with a slightly less electronegative SH thiol group. We hypothesized that this exchange would lead to a more pronounced shift in the preference of phenylpyruvate compared to hydroxyphenylpyruvate, thereby increasing production of MA. However, the expression of *N. uniformis* HmaS^S195C^ from plasmid MRV140 in strain Y4 (CEN.PK2-1C *TRP1* Shik↑ *aro10Δ aro8Δ pdc5Δ*, [@bib43]) grown in SMD medium only led to a severe decrease in HMA titers and no increase in MA titers ([Fig. 2](#f0010){ref-type="fig"}A and B).Fig. 2In vivo hydroxymandelic acid and mandelic acid production by engineered HmaS variants. A) Hydroxymandelic acid (HMA) titers and B) mandelic acid (MA) titers of Y4 (CEN.PK2-1C *TRP1* Shik↑ *aro10Δ aro8Δ pdc5Δ*, [@bib43]) expressing the different variants of *N. uniformis hmaS*. The fermentations were performed in SMD (20 g/L glucose) without supplementation of aromatic amino acids and with a starting OD~600~ of 5. Error bars indicate standard deviation of biological duplicates.Fig. 2

Additionally, we tested active site mutations as published by [@bib41] who discovered *Streptomyces coelicolor* HmaS mutants with improved steady state kinetics (higher k~cat~^app^ and higher k~cat~^app^/K~M~^app^) for phenylpyruvate conversion. Actually, [@bib41] mainly aimed for an inversion of the enantioselectivity of the enzyme for the production of R-MA instead of S-MA. Additionally, they observed that the two mutant versions with highest selectivity for R-MA production (S221M+V223M+Y359A and S221M+V223F+Y359A) also showed improved steady state characteristics for MA production. They did not analyze steady state kinetics with hydroxyphenylpyruvate as a substrate but as the serine forming the hydrogen bond with the *para*-hydroxy group of hydroxyphenylpyruvate (S221) was replaced by a methionine in both mutants, a negative effect on HMA production was most likely. Aiming for increased MA production, we therefore transferred the corresponding mutations to the HmaS of *N. uniformis* (S195M+V197M+Y333A and S195M+V197F+Y333A) and tested the variants in *S. cerevisiae*. However, after expressing the *hmaS* variants (plasmids MRV141 and MRV142) in strain Y4 (CEN.PK2-1C *TRP1* Shik↑ *aro10Δ aro8Δ pdc5Δ*, [@bib43]) grown in SMD medium, no positive effect on MA production could be detected although the HMA titers dropped as expected ([Fig. 2](#f0010){ref-type="fig"}A and B).

To conclude, all mutations that we introduced into the active site of HmaS did not yield the desired effects of increased MA production documenting the difficulties of rational enzyme engineering. One solution could be a sensor system allowing to screen for improved MA production to make the identification of mutants with increased activity towards phenylpyruvate possible. However, to our knowledge such a sensor system, which would require sensitivity to MA and should not sense HMA, is not yet available.

3.2. Compartmentalizing the mandelic acid biosynthetic pathway in peroxisomes and mitochondria {#s0045}
----------------------------------------------------------------------------------------------

As the amino acid replacements introduced into the HmaS active site did not improve MA production, we shifted our strategy towards pathway compartmentalization. We aimed to increase flux into the phenylalanine branch and decrease flux into the tyrosine branch by locating the three consecutive enzymatic reactions catalyzed by Aro7, Pha2 and HmaS into mitochondria or peroxisomes. Localizing these three enzymes into one compartment should favor production of phenylpyruvate and MA due to spatial separation of the MA production pathway from the competing enzyme Tyr1 and the competing substrate hydroxyphenylpyruvate ([Fig. 1](#f0005){ref-type="fig"}). During yeast fermentations, intermediates of the aromatic amino acid pathway can be found in culture supernatants ([@bib33]). Even though no specific transporters for these hydrophilic molecules are known, transport via unspecific or unknown transporters might allow their release into the medium ([@bib19], [@bib42]). In the same way, unspecific transport across mitochondrial membranes might occur and peroxisomal membranes have been shown to be highly permeable to small hydrophilic molecules ([@bib12]). Therefore, we reasoned that uptake of chorismate into and release of MA out of the organelles should not be a major problem. Moreover, a minor fraction of prephenate must be transported back into the cytosol to be available for tyrosine production via Tyr1.

We chose a feedback resistant version of Aro7 (Aro7^fbr^, G141S, according to [@bib47]) to avoid the inhibiting influence of aromatic amino acid levels on chorismate mutase activity. We constructed plasmids from which *ARO7*^*fbr*^, *PHA2* and *hmaS* from *N. uniformis* were expressed -- either with or without a mitochondrial or a peroxisomal targeting sequence, *MTS* or *ePTS1*, respectively (for codon-optimized sequences see [Supplementary table S4](#s0075){ref-type="sec"}). We chose the mitochondrial targeting sequence of *N. crassa* ATP synthase subunit 9, which was previously shown to efficiently localize proteins to the mitochondria of *S. cerevisiae* ([@bib3], [@bib54], [@bib55]). For peroxisomal localization we chose the enhanced peroxisomal targeting sequence ePTS1 that was identified by [@bib12] and shown to cause efficient protein relocation into peroxisomes. Fluorescence microscopy performed with CEN.PK2-1C ([@bib16]) expressing *MTS-ARO7*^*fbr*^ or *ARO7*^*fbr*^*-ePTS1* tagged with superfolder GFP ([@bib40]), *MTS- ARO7*^*fbr*^*-sfGFP* and *sfGFP-ARO7*^*fbr*^*-ePTS1*, respectively, indicated that MTS and ePTS1 directed the proteins to the respective organelles ([Fig. 3](#f0015){ref-type="fig"}A and B).Fig. 3Pathway compartmentalization in mitochondria and peroxisomes of *S. cerevisiae* for mandelic acid production. A) and B) Intracellular localization of ~mit~Aro7^fbr^-sfGFP and sfGFP-~perox~Aro7^fbr^, respectively, visualized by fluorescence microscopy. CEN.PK2-1C cells expressing *MTS-ARO7*^*fbr*^*-sfGFP* (A) and *sfGFP-ARO7*^*fbr*^*-ePTS1* (B) from plasmids were grown until the exponential phase in lf-SCD medium. The scale bars indicate 2 µm. C) and D) mandelic acid (MA, top) and hydroxymandelic acid (HMA, bottom) titers after 24 h of fermentation with MRY25 (CEN.PK2-1C *TRP1* Shik↑ *aro7Δ trp2Δ*) with Aro7^fbr^, Pha2 and *N. uniformis* HmaS targeted to mitochondria (M, red), cytosol (C, blue) or peroxisomes (P, green). Plain-colored bars present samples in which all three consecutive enzymes were localized in one compartment (blue, cytosol; red, mitochondria; green, peroxisomes). The fermentation was performed in SMD (20 g/L glucose) with anthranilate supplementation and a starting OD~600~ of 5. Error bars indicate standard deviation of biological duplicates (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).Fig. 3

Next, we tested whether Aro7^fbr^ and Pha2 remain active when they are targeted to mitochondria or peroxisomes. A growth test with *aro7* or *pha2* deletion strains showed that both the mitochondrial and peroxisomal versions of Aro7^fbr^ and Pha2 could replace the missing cytosolic reactions and enabled growth on media without aromatic amino acid supplementation (see [Supplementary Fig. S1A and B](#s0075){ref-type="sec"}). Only in case of *MTS-ARO7*^*fbr*^ expression in an *aro7Δ* strain, the growth test showed a slight reduction in growth in comparison to cytosolic *ARO7*^*fbr*^ expression (see [Supplementary Fig. S1A](#s0075){ref-type="sec"}). Overall, the growth tests suggested that transporters or pores in the organellar membranes ([@bib12], [@bib39]) allow passage of chorismate, prephenate and phenylpyruvate. However, we cannot exclude that a minor fraction of the MTS of ePTS1 fusion proteins remained in the cytosol.

Having shown that Aro7^fbr^ and Pha2 targeted to mitochondria (~mit~Aro7^fbr^ and ~mit~Pha2, respectively) and peroxisomes (~perox~Aro7^fbr^ and ~perox~Pha2, respectively) are active, we fermented with the *aro7*[*Δ*]{.ul} strain MRY25 (CEN.PK2-1C *TRP1* Shik↑ *aro7Δ trp2Δ*) expressing from plasmids *ARO7*^*fbr*^, *PHA2* and *hmaS* with or without added targeting sequences and analyzed MA and HMA titers ([Fig. 3](#f0015){ref-type="fig"}C and D). Besides the expression of *PHA2* variants from a plasmid, *PHA2* was additionally expressed from the genome as MRY25 only carried an *aro7* deletion but no *pha2* deletion. The presence of additional cytosolically localized Pha2 needs to be considered when interpreting the fermentation results.

When ~mit~Aro7^fbr^, ~mit~Pha2 and ~mit~HmaS were used, the titer of MA increased threefold whereas the HMA titer decreased 9-fold in comparison to the cytosolically localized enzymes ([Fig. 3](#f0015){ref-type="fig"}C, red vs. blue bars). A similar but weaker tendency was seen for ~perox~Aro7^fbr^, ~perox~Pha2 and ~perox~HmaS. Here, the MA titer increased 1.6-fold whereas the HMA titer decreased only slightly in comparison to the cytosolically localized enzymes ([Fig. 3](#f0015){ref-type="fig"}D, green vs. blue bars). In both cases, peroxisomal or mitochondrial targeting of Aro7^fbr^, Pha2 and HmaS was beneficial for MA production.

For the controls where solely Pha2 was localized in mitochondria or peroxisomes, we expected an increased conversion of prephenate by Tyr1 resulting in enhanced HMA production. The results for Aro7^fbr^+~mit/perox~Pha2+HmaS confirmed this hypothesis ‒ the MA concentration dropped and the HMA concentration increased slightly in comparison to the cytosolic control ([Fig. 3](#f0015){ref-type="fig"}C and D, grey bars with blue border *vs*. blue bars).

Interestingly, when Aro7^fbr^ and HmaS were localized in mitochondria (~mit~Aro7^fbr^, ~(mit)~Pha2 and ~mit~HmaS, [Fig. 3](#f0015){ref-type="fig"}C) the HMA titers decreased strongly from 94 mg/L to less than 20 mg/L. This might suggest a limited permeability of the mitochondrial membrane for hydroxyphenylpyruvate or HMA. For peroxisomal localization of Aro7 and HmaS we detected a much weaker effect on HMA levels (~perox~Aro7^fbr^, ~(perox)~Pha2 and ~perox~HmaS, [Fig. 3](#f0015){ref-type="fig"}D), which can be explained by the high permeability of the peroxisomal membrane to small hydrophilic molecules ([@bib12]).

Unexpectedly, we detected increased MA for the controls where only the second enzyme Pha2 was localized in the cytosol and the two other enzymes were localized in the organelles (~mit/perox~Aro7^fbr^, Pha2 and ~mit/perox~HmaS, [Fig. 3](#f0015){ref-type="fig"}C and D, grey bars with red/green border). As the second out of the three enzymes was not localized in the respective organelle we had expected a decrease in MA production. Furthermore, the titers of the Ehrlich pathway products phenylacetic acid and phenylethanol remained inconclusive (see [Supplementary Fig. S2](#s0075){ref-type="sec"}). We detected a strong decrease in phenylacetic acid and phenylethanol (PAA+PET) titers when Aro7^fbr^, Pha2 and HmaS were localized in mitochondria, but also when the second enzyme Pha2 was localized in the cytosol ([Supplementary Fig. S2A](#s0075){ref-type="sec"}). For peroxisomal localization of the enzymes the phenylacetic acid and phenylethanol (PAA+PET) titers remained nearly unchanged ([Supplementary Fig. S2B](#s0075){ref-type="sec"}).

The results described were unexpected - from pathway compartmentalization we had expected advantages for MA production due to the following circumstances: (1) production of prephenate inside the organelle (catalyzed by ~mit/perox~Aro7^fbr^) whereas the competing enzyme Tyr1 is localized in the cytosol; (2) production of phenylpyruvate inside the organelle (catalyzed by ~mit/perox~Pha2) whereas the competing Ehrlich pathway enzymes are localized in the cytosol; (3) cytosolic production of the competing substrate hydroxyphenylpyruvate (catalyzed by Tyr1) whereas ~mit/perox~Pha2 produces phenylpyruvate within the organelle where also ~mit/perox~HmaS is localized and (4) clustering of enzymes leading to a channeling effect ([@bib7]) (see [Fig. 1](#f0005){ref-type="fig"}).

However, our results -- especially the controls where only the second enzyme Pha2 was localized in the cytosol -- did not entirely support the above-mentioned hypotheses. We therefore conclude that our observations are the result of an interplay of several factors like (restricted) permeability of the organellar membranes, regulation on expressional level, varying enzyme activities depending on their localization (organelle vs. cytosol) together with the desired pathway compartmentalization effects.

Altogether, we could show that pathway compartmentalization had a beneficial effect on the shift from HMA to MA production. However, regarding the ambiguous results and the low MA titers (2.7 mg/L in mitochondria and 2.6 mg/L in peroxisomes) we conclude that even though peroxisomal and mitochondrial pathway compartmentalization positively influenced MA production, it is not a promising option for future applications.

3.3. Using the bifunctional enzyme PheA leads to increased mandelic acid production {#s0050}
-----------------------------------------------------------------------------------

As an alternative approach to shift production from HMA to MA in *S. cerevisiae*, we used the bifunctional *E. coli* enzyme PheA in an *aro7Δ* strain. PheA has both chorismate mutase and prephenate dehydratase activity and converts chorismate to phenylpyruvate via prephenate (see [Fig. 1](#f0005){ref-type="fig"}). We assumed that in PheA some kind of substrate channeling might occur ([@bib7]), thereby favoring the flux of prephenate towards phenylpyruvate over the flux towards hydroxyphenylpyruvate. We used a feedback resistant version of PheA (PheA^fbr^, ΔT304, G305K and ΔQ306; according to [@bib36]; codon-optimized sequence in [Supplementary Table S4](#s0075){ref-type="sec"}).

First, we tested in a growth test whether the chorismate mutase domain of PheA^fbr^ is active in *S. cerevisiae* and whether *pheA*^*fbr*^ expression impairs growth on medium without tyrosine. We therefore grew the *aro7Δ* strain MRY36 expressing *pheA*^*fbr*^ (and *hmaS*) on SMD medium without supplementation of aromatic amino acids ([Fig. 4](#f0020){ref-type="fig"}A). MRY36 expressing *pheA*^*fbr*^ (±* hmaS*) grew comparable to MRY36 expressing *ARO7fbr* (±* PHA2*, ±* hmaS*) confirming that the chorismate mutase domain of PheA^fbr^ is active in *S. cerevisiae*. Additionally, the results showed that the intermediate prephenate is also still available for prephenate dehydrogenase Tyr1 to be further converted to tyrosine.Fig. 4Using the bifunctional *E. coli* enzyme PheA^fbr^ for mandelic acid production in an *aro7Δ S. cerevisiae* strain. A) Growth test with MRY36 (CEN.PK2-1C *TRP1* Shik↑ *aro10Δ aro8Δ pdc5Δ aro7Δ*) cells harboring different plasmid combinations on SMD with and without supplementation of aromatic amino acids. Cell dilutions of OD~600~ 1, 10^−1^, 10^−2^ and 10^−3^ (from left to right, respectively) were used. The picture was taken after 3d at 30 °C. EV, empty vector. B), C) and D) Production of mandelic acid (MA, B), hydroxymandelic acid (HMA, C) and phenylacetic acid + phenylethanol (PAA+PET, D) by the *aro7Δ* strain MRY36 expressing either *pheA*^*fbr*^ and *hmaS* (red) or *ARO7*^*fbr*^, *PHA2* and *hmaS* (blue). E) Fermentation with the *aro7Δ* strain MRY36 harboring the *hmaS-pheA*^*fbr*^ plasmid MRV144. MA, glucose and ethanol titers and OD~600~ in SMD without supplementation of aromatic amino acids. The fermentations were performed in SMD (20 g/L glucose) without supplementation aromatic amino acids and with a starting OD~600~ of 5. Error bars indicate standard deviation of biological duplicates (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).Fig. 4

Furthermore, we also found that PheA^fbr^ can replace the prephenate dehydratase Pha2 of *S. cerevisiae* as expression of *pheA*^*fbr*^ in a *pha2Δ* strain (MRY15, CEN.PK2-1C *TRP1* Shik↑ *pha2Δ*) enabled growth on medium without phenylalanine (see growth test in [Supplementary Fig. S4](#s0075){ref-type="sec"}).

Having confirmed that both the chorismate mutase and the prephenate dehydratase domain of PheA^fbr^ are active in *S. cerevisiae*, we tested PheA^fbr^ together with the HmaS of *N. uniformis* in a fermentation using the *aro7Δ* strain MRY36. The fermentation was performed in SMD medium without amino acid supplementation. We compared cells expressing *pheA*^*fbr*^ and *hmaS* with cells expressing *ARO7*^*fbr*^, *PHA2* and *hmaS* (see [Fig. 4](#f0020){ref-type="fig"}B-D). Upon expression of *ARO7*^*fbr*^*, PHA2* and *hmaS* 9.5 mg/L MA was produced after 120 h ([Fig. 4](#f0020){ref-type="fig"}B). When *hmaS* was expressed together with *pheA*^*fbr*^ instead, the MA titer increased to 36 mg/L ([Fig. 4](#f0020){ref-type="fig"}B). Additionally, a strong increase of the Ehrlich pathway products phenylacetic acid and phenylethanol confirmed that PheA^fbr^ caused an increased flux into the phenylalanine biosynthesis branch ([Fig. 4](#f0020){ref-type="fig"}D). Furthermore, HMA titers decreased 4-fold when *pheA*^*fbr*^ was expressed instead of *ARO7*^*fbr*^ and *PHA2* ([Fig. 4](#f0020){ref-type="fig"}C).

The increased flux into the phenylalanine branch upon expression of *pheA*^*fbr*^ could be caused by a higher prephenate dehydratase activity of PheA^fbr^ in comparison to Pha2 or by a substrate channeling effect. PheA is a well-studied enzyme and its catalytic efficiency was analyzed in several in vitro studies ([@bib13], [@bib29], [@bib31], [@bib58]). However, these studies were performed under different conditions and reported varying K~M~ and k~cat~ values. Additionally, we did not find in vitro studies analyzing the catalytic efficiency of Pha2 which would allow comparing the prephenate dehydratase activities of Pha2 and PheA. Several studies on PheA suggest that there is no channeling or at least no tight channeling of prephenate from the chorismate mutase domain to the prephenate dehydratase domain ([@bib15], [@bib58], [@bib57]). This is in accordance with our results which show that at least a fraction of prephenate diffuses from PheA to enter the tyrosine branch (growth test [Fig. 4](#f0020){ref-type="fig"}A and fermentation [Fig. 4](#f0020){ref-type="fig"}C). However, this does not exclude that partial channeling between the two domains or channeling due to enzyme clustering ([@bib7]) could occur.

To conclude, there are several possible explanations for the effect seen for *pheA*^*fbr*^ expression in *S. cerevisiae*. Either way, using PheA^fbr^ in *S. cerevisiae* enabled us to significantly increase MA production in comparison to the same strain overexpressing the individual yeast genes *ARO7*^*fbr*^ and *PHA2*.

3.4. Expressing *pheA*^*fbr*^ and *hmaS* from a single plasmid further increases mandelic acid production {#s0055}
---------------------------------------------------------------------------------------------------------

In the experiments described in chapter 3.3, every gene was expressed from an individual plasmid so that each cell contained three plasmids. As this might cause heterogeneous expression of the genes on single cell level ([@bib30]) and/or plasmid burden effects ([@bib28]), we constructed a single plasmid from which both *pheA*^*fbr*^ and *hmaS* were expressed. We first created a new *hmaS* construct where we replaced the methionine repressible *MET25*~*prom*~ promoter by the strong constitutive *ZEO1*~*prom*~ promoter ([@bib50]) and the *CYC1*~ter~ by the expression-enhancing *PRM9*~*ter*~ terminator ([@bib10]) (plasmid MRV143). The new plasmid MRV143 did not lead to higher MA and HMA production when compared to the original *hmaS* plasmid MRV104 (see [Supplementary Fig. S4](#s0075){ref-type="sec"}).

Nevertheless, we used *ZEO1*~*prom*~*-hmaS-PRM9*~*ter*~ to construct the *hmaS-pheA*^*fbr*^ plasmid MRV144 (*ZEO1*~*prom*~*-hmaS-PRM9*~*ter*~ + *HXT7*~*prom*~*-pheA*^*fbr*^*-CYC1*~*ter*~, see [Supplementary Table S1](#s0075){ref-type="sec"}). Intriguingly, the *aro7*Δ strain MRY36 harboring the new *hmaS-pheA*^*fbr*^ plasmid MRV144 reached MA titers up to 120 mg/L after 120 h ([Fig. 4](#f0020){ref-type="fig"}E), which is a threefold increase compared to MRY36 expressing the genes from individual plasmids ([Fig. 4](#f0020){ref-type="fig"}B). The yield of MA after 120 h was 5.6 (± 0.5) mg/g glucose. The results outline the strong impact of heterogeneity on single cell level ([@bib30]) and/or plasmid burden effects ([@bib28]) when using several 2 µ plasmids for enzyme expression. A genomic integration of multiple copies of *pheA*^*fbr*^ and *hmaS* could further reduce plasmid burden effects and might yield even higher MA levels.

Overall, using PheA^fbr^ increased MA titers 12-fold from 10 mg/L to 120 mg/L. This titer is approximately half of what we achieved in our previous study (236 mg/L MA, [@bib43]). However, the strain used in that previous work was auxotrophic for all aromatic amino acids, barely grew within 120 h (from OD~600~ = 5 to OD~600~ = 6) and did not fully consume glucose and ethanol after 120 h in medium supplemented with aromatic amino acids ([@bib43]). The MA producer strain constructed in this study (*aro7Δ* strain MRY36 harboring the *hmaS-pheA*^*fbr*^ plasmid MRV144) did not need supplementation of any aromatic amino acid, grew well during the fermentation (from OD~600~ = 5 to OD~600~ = 11) and completely consumed glucose and ethanol ([Fig. 4](#f0020){ref-type="fig"}E).

3.5. Conclusion and outlook {#s0060}
---------------------------

We tested three different strategies to increase mandelic acid production in tyrosine prototrophic *S. cerevisiae* strains: (1) engineering the active site of HmaS, (2) compartmentalizing the MA pathway and (3) using a feedback resistant form of the bifunctional chorismate mutase-prephenate dehydratase PheA from *E. coli* (scheme in [Fig. 1](#f0005){ref-type="fig"}). The third approach was most promising. Expression of *pheA*^*fbr*^ together with *hmaS* from a single plasmid in the *aro7Δ S. cerevisiae* strain MRY36 increased MA production 12-fold (comp. [Fig. 4](#f0020){ref-type="fig"}A and E). With PheA^fbr^, we achieved our goal of demonstrating a promising strategy to create a prototrophic MA producer strain. Moreover, our results suggest that using PheA^fbr^ in *S. cerevisiae* is very interesting also for the production of other phenylalanine branch derived compounds such as phenylethanol or heterologous *trans*-cinnamic acid derivatives like styrene, pinocembrin dihydrochalcone, cinnamaldehyde and cinnamyl alcohol ([@bib23], [@bib48]).
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